Treatment of Refractory Cough in Idiopathic Pulmonary Fibrosis (IPF)

Initial Assessment and Management

The American College of Chest Physicians recommends assessing for progression of underlying IPF or complications from immunosuppressive treatment before initiating specific cough treatments 1
Evaluate for common comorbidities that may contribute to cough, including gastroesophageal reflux disease (GERD), obstructive sleep apnea, and pulmonary hypertension 2
If GERD workup is negative, proton pump inhibitor therapy should not be prescribed for cough management, as recommended by the American College of Chest Physicians 3, 4

Gabapentin therapy is recommended as a first-line option, following dosing protocols as recommended for unexplained chronic cough, according to the American College of Chest Physicians 1, 5
Multimodality speech pathology therapy, including cough suppression techniques and breathing exercises, is also recommended as a first-line option 6, 5
The American College of Chest Physicians recommends low-dose controlled-release morphine as a second-line option, with regular reassessment of benefits and risks 6

The 2018 American College of Chest Physicians guidelines provide consensus-based recommendations due to limited high-quality evidence specifically for IPF-related cough 1, 6
Cough in IPF has prognostic significance and is associated with disease progression, independent of disease severity, as noted by the American College of Chest Physicians 2
Up to 80% of IPF patients experience chronic cough, which significantly impairs quality of life, according to the American College of Chest Physicians 2

For patients with chronic cough due to IPF that adversely affects quality of life and is refractory to other treatments, opiates should be considered in a palliative care setting, as recommended by the American College of Chest Physicians 6, 4
Regular reassessment of benefits versus risks is essential when using opiates for symptom control, according to the American College of Chest Physicians 6

Low‑dose controlled‑release morphine (≤ 30 mg oral morphine equivalents per day) may be used as second‑line therapy for refractory IPF‑associated cough when first‑line options fail. Regular benefit‑risk reassessment is required. European Respiratory Review recommends confirming the absence of hypercapnia before initiation. 7

Proton‑pump inhibitors (PPIs) should not be prescribed for IPF‑related cough unless gastro‑oesophageal reflux disease is objectively documented. The American College of Chest Physicians advises against PPI use in patients with a negative GERD work‑up, noting that PPIs do not reduce objective cough counts even when acid reflux improves. 8
Systemic corticosteroids are not recommended for routine cough control in IPF. Evidence from the American College of Chest Physicians links systemic steroids used as “triple therapy” to increased mortality in IPF. They should be reserved for acute IPF exacerbations or co‑existing asthma/eosinophilic bronchitis; a brief low‑dose course may be considered only for incapacitating dry cough unresponsive to codeine, which does not apply to productive cough. 9 [7]
Inhaled corticosteroids lack supporting evidence for treating IPF‑associated cough and are therefore not advised as routine therapy. 9
Thalidomide should be avoided despite limited efficacy data, due to significant side‑effect risk and lack of endorsement by current guidelines. 9 [8]
Antifibrotic agents (pirfenidone or nintedanib) should be continued or initiated to optimize underlying IPF management, although they are not specifically indicated for cough relief. 9

When using opioid‑based cough suppression (e.g., morphine), clinicians must monitor for hypercapnia and adjust therapy accordingly. 7
Adequate oxygen therapy should be ensured and optimized for patients with IPF on home oxygen, as part of overall symptom management. 7